INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
August 21, 2019 09:49 ET
|
Schall Law
LOS ANGELES, Aug. 21, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abiomed, Inc. (“Abiomed” or...
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
August 14, 2019 09:24 ET
|
Schall Law
LOS ANGELES, Aug. 14, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abiomed, Inc. (“Abiomed” or...
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
August 09, 2019 13:14 ET
|
Schall Law
LOS ANGELES, Aug. 09, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abiomed, Inc. (“Abiomed” or...
New Study with Abiomed’s Impella 2.5® Heart Pump Demonstrates Potential Survival with Pre-PCI Insertion in Heart Attacks with the Left Main Coronary Artery
June 30, 2017 08:04 ET
|
Abiomed
DANVERS, Mass., June 30, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today the recent publication of a...
Heart Recovery Patients Visit Capitol Hill to Advocate for Lifesaving Cardiovascular Technology
June 09, 2017 08:07 ET
|
Abiomed
WASHINGTON, June 09, 2017 (GLOBE NEWSWIRE) -- Nineteen patients who benefitted from treatment with Abiomed’s Impella heart pumps traveled to Washington, D.C. on June 8, 2017, to meet with elected...
Abiomed Introduces 3rd Generation Impella CP® Heart Pumps at SCAI 2017
May 09, 2017 09:33 ET
|
Abiomed
DANVERS, Mass., May 09, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced the debut of the 3rd Generation...
First-Ever Presentation on Abiomed’s Impella® Quality (IQ) Assurance Program and Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery at the 2017 American College of Cardiology Scientific Session
March 19, 2017 14:30 ET
|
Abiomed
- Real-World Data Representing 15,259 Patients WASHINGTON, March 19, 2017 (GLOBE NEWSWIRE) -- Data from Abiomed’s (NASDAQ:ABMD) Impella® Quality (IQ) Assurance Program, which includes the IQ...
Abiomed's Impella® Technology Showcased at 2017 American College of Cardiology Scientific Session With More Than 10 Presentations
March 16, 2017 08:00 ET
|
Abiomed
DANVERS, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announces that there are more than 10...
New Study Finds Abiomed Impella® Heart Pump Reduces Injury to Kidneys During High-Risk Percutaneous Coronary Intervention
March 09, 2017 08:00 ET
|
Abiomed
DANVERS, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- A new study published in Circulation Research finds use of hemodynamic support with Impella® 2.5 heart pump during high-risk percutaneous coronary...
Abiomed Surpasses 50,000 Impella® Patients Treated in the United States
February 23, 2017 14:00 ET
|
Abiomed
DANVERS, Mass., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announced that it has supported more than 50,000...